tirzepatide molecule File:Tirzepatide structure.svg Tirzepatide (LY-3298176) | GIP/GLP-1 agonist
Description
Injecting in the same spot repeatedly can cause lipodystrophy, a condition where fat either builds up abnormally or atrophies, potentially affecting medication absorption
The LEADER trial showed that Victoza reduced the risk of major cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 13% compared to placebo in patients with type 2 diabetes and high cardiovascular risk
10.1053/j.gastro.2016.09.007 99 TsukudaN.YahagiK.HaraT.WatanabeY.MatsumotoH.MoriH.et al (2021)
Cmo controlar mejor las porciones
Pennsylvania started paying for GLP-1 drugs for obesity in 2023
Preprints 2023, 2023090416.
